1. Short title This Act may be cited as the Affordable Prescriptions for Patients Act of 2019 . 2. Product hopping; patent thicketing (a) In general The Federal Trade Commission Act ( 15 U.S.C. 41 et seq.) is amended by inserting after section 26 ( 15 U.S.C. 57c–2 ) the following: 27. Product hopping; patent thicketing (a) Definitions In this section: (1) Abbreviated new drug application The term abbreviated new drug application means an application under subsection (b)(2) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ). (2) Biosimilar biological product The term biosimilar biological product means a biological product licensed under section 351(k) of the Public Health Service Act ( 42 U.S.C. 262(k) ). (3) Biosimilar biological product license application The term biosimilar biological product license application means an application submitted under section 351(k) of the Public Health Service Act ( 42 U.S.C. 262(k) ). (4) Competition window The term competition window means— (A) with respect to a listed drug, the period between— (i) the date that is the earlier of— (I) 8 years before any patent or marketing exclusivity granted under chapter V of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 351 et seq.) with respect to such listed drug expires; and (II) the date on which the first abbreviated new drug application that references such listed drug is filed; and (ii) the later of— (I) the date that is 180 days after the first abbreviated new drug application that references such listed drug is filed; and (II) the date that is 1 year after the date on which the generic drug that is the subject of the abbreviated new drug application described in subclause (I) enters the marketplace